文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

巴瑞替尼通过抑制 JAK/STAT 通路减少大鼠失血性休克引起的多器官功能障碍。

Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats.

机构信息

William Harvey Research Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London, London, UK.

Department of Neurosciences "Rita Levi Montalcini," University of Turin, Turin, Italy.

出版信息

Ann Surg. 2023 Jul 1;278(1):e137-e146. doi: 10.1097/SLA.0000000000005571. Epub 2022 Jul 15.


DOI:10.1097/SLA.0000000000005571
PMID:35837955
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10249600/
Abstract

OBJECTIVE: The aim of this study was to investigate (a) the effects of the Janus kinase (JAK)/signal transducer and activator of transcription (STAT) pathway inhibitor (baricitinib) on the multiple organ dysfunction syndrome (MODS) in a rat model of hemorrhagic shock (HS) and (b) whether treatment with baricitinib attenuates the activation of JAK/STAT, NF-κB, and NLRP3 caused by HS. BACKGROUND: Posttraumatic MODS, which is in part due to excessive systemic inflammation, is associated with high morbidity and mortality. The JAK/STAT pathway is a regulator of numerous growth factor and cytokine receptors and, hence, is considered a potential master regulator of many inflammatory signaling processes. However, its role in trauma-hemorrhage is unknown. METHODS: An acute HS rat model was performed to determine the effect of baricitinib on MODS. The activation of JAK/STAT, NF-κB, and NLRP3 pathways were analyzed by western blotting in the kidney and liver. RESULTS: We demonstrate here for the first time that treatment with baricitinib (during resuscitation following severe hemorrhage) attenuates the organ injury and dysfunction and the activation of JAK/STAT, NF-κB, and NLRP3 pathways caused by HS in the rat. CONCLUSIONS: Our results point to a role of the JAK/STAT pathway in the pathophysiology of the organ injury and dysfunction caused by trauma/hemorrhage and indicate that JAK inhibitors, such as baricitinib, may be repurposed for the treatment of the MODS after trauma and/or hemorrhage.

摘要

目的:本研究旨在探讨(a)Janus 激酶(JAK)/信号转导和转录激活因子(STAT)通路抑制剂(巴瑞替尼)对失血性休克(HS)大鼠模型多器官功能障碍综合征(MODS)的影响,以及(b)巴瑞替尼是否能减轻 HS 引起的 JAK/STAT、NF-κB 和 NLRP3 的激活。

背景:创伤后 MODS 部分是由于过度的全身炎症引起的,与高发病率和死亡率相关。JAK/STAT 通路是许多生长因子和细胞因子受体的调节剂,因此被认为是许多炎症信号转导过程的潜在主调节剂。然而,其在创伤性出血中的作用尚不清楚。

方法:采用急性 HS 大鼠模型,观察巴瑞替尼对 MODS 的影响。通过 Western blot 分析肾和肝中 JAK/STAT、NF-κB 和 NLRP3 通路的激活。

结果:我们首次证明,巴瑞替尼(在严重出血后复苏期间)治疗可减轻 HS 引起的大鼠器官损伤和功能障碍以及 JAK/STAT、NF-κB 和 NLRP3 通路的激活。

结论:我们的研究结果表明 JAK/STAT 通路在创伤/出血引起的器官损伤和功能障碍的病理生理学中发挥作用,并表明 JAK 抑制剂,如巴瑞替尼,可能被重新用于治疗创伤和/或出血后的 MODS。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/14bea887a7d3/sla-278-e137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/50c14d99d550/sla-278-e137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/f358eb977ecc/sla-278-e137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/910c648dc658/sla-278-e137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/189ed2b2f64f/sla-278-e137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/1fa329208d03/sla-278-e137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/14bea887a7d3/sla-278-e137-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/50c14d99d550/sla-278-e137-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/f358eb977ecc/sla-278-e137-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/910c648dc658/sla-278-e137-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/189ed2b2f64f/sla-278-e137-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/1fa329208d03/sla-278-e137-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1f50/10249600/14bea887a7d3/sla-278-e137-g006.jpg

相似文献

[1]
Inhibition of the JAK/STAT Pathway With Baricitinib Reduces the Multiple Organ Dysfunction Caused by Hemorrhagic Shock in Rats.

Ann Surg. 2023-7-1

[2]
Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.

Ann Surg. 2023-3-1

[3]
Inhibition of Macrophage Migration Inhibitory Factor Activity Attenuates Haemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.

Front Immunol. 2022

[4]
Impact of heat stress on prolactin-mediated ovarian JAK-STAT signaling in postpubertal gilts.

J Anim Sci. 2022-7-1

[5]
Dietary oleuropein and its new acyl-derivate attenuate murine lupus nephritis through HO-1/Nrf2 activation and suppressing JAK/STAT, NF-κB, MAPK and NLRP3 inflammasome signaling pathways.

J Nutr Biochem. 2019-9-13

[6]
Role of the JAK/STAT signaling pathway in the pathogenesis of acute myocardial infarction in rats and its effect on NF-κB expression.

Mol Med Rep. 2012-10-29

[7]
Sitagliptin and tofacitinib ameliorate adjuvant induced arthritis via modulating the cross talk between JAK/STAT and TLR-4/NF-κB signaling pathways.

Life Sci. 2020-8-12

[8]
Baricitinib protects mice from sepsis-induced cardiac dysfunction and multiple-organ failure.

Front Immunol. 2023

[9]
Chaiqin Chengqi decoction inhibits inflammatory mediators and attenuates acute pancreatitis through deactivation of janus kinase/signal transducer and activator of transcription signaling pathway.

J Tradit Chin Med. 2019-4

[10]
JAK-STAT inhibition reduces endothelial prothrombotic activation and leukocyte-endothelial proadhesive interactions.

J Thromb Haemost. 2023-5

引用本文的文献

[1]
Combined Metformin and Baricitinib Therapy Attenuates Inflammation in STZ-Induced Diabetic Rats via AMPK/JAK-STAT Pathway Crosstalk.

Endocrinol Diabetes Metab. 2025-9

[2]
Immune inflammation and metabolic interactions in the pathogenesis of diabetic nephropathy.

Front Endocrinol (Lausanne). 2025-7-8

[3]
Crosstalk between ferroptosis and innate immune in diabetic kidney disease: mechanisms and therapeutic implications.

Front Immunol. 2025-2-28

[4]
L. alleviates acute lung injury in human A-549 cells by reducing NF-κB and NLRP3 inflammasome signaling.

Pharm Biol. 2025-12

[5]
Emerging and reemerging infectious diseases: global trends and new strategies for their prevention and control.

Signal Transduct Target Ther. 2024-9-11

[6]
NLRP3 Inflammasomes: Dual Function in Infectious Diseases.

J Immunol. 2024-8-15

[7]
The New Nano-Resuscitation Solution (TPP-MR) Attenuated Myocardial Injury in Hemorrhagic Shock Rats by Inhibiting Ferroptosis.

Int J Nanomedicine. 2024

[8]
Off-label use of Baricitinib improves moderate and severe atopic dermatitis in China through inhibiting MAPK and PI3K/Akt/mTOR pathway via targeting JAK-STAT signaling of CD4 cells.

Front Pharmacol. 2024-2-29

[9]
Transforming research to improve therapies for trauma in the twenty-first century.

Crit Care. 2024-2-13

[10]
The oncogenic mechanisms of the Janus kinase-signal transducer and activator of transcription pathway in digestive tract tumors.

Cell Commun Signal. 2024-1-25

本文引用的文献

[1]
Inhibition of Macrophage Migration Inhibitory Factor Activity Attenuates Haemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.

Front Immunol. 2022

[2]
Inhibition of Bruton's Tyrosine Kinase Activity Attenuates Hemorrhagic Shock-Induced Multiple Organ Dysfunction in Rats.

Ann Surg. 2023-3-1

[3]
Real-Life Effectiveness and Safety of Baricitinib as Adjunctive to Standard-of-Care Treatment in Hospitalized Patients With Severe Coronavirus Disease 2019.

Open Forum Infect Dis. 2021-11-22

[4]
Clinical efficacy and adverse events of baricitinib treatment for coronavirus disease-2019 (COVID-19): A systematic review and meta-analysis.

J Med Virol. 2022-4

[5]
Plasma and rhADAMTS13 reduce trauma-induced organ failure by restoring the ADAMTS13-VWF axis.

Blood Adv. 2021-9-14

[6]
Efficacy and safety of baricitinib for the treatment of hospitalised adults with COVID-19 (COV-BARRIER): a randomised, double-blind, parallel-group, placebo-controlled phase 3 trial.

Lancet Respir Med. 2021-12

[7]
Janus Kinase Inhibition Ameliorates Ischemic Stroke Injury and Neuroinflammation Through Reducing NLRP3 Inflammasome Activation JAK2/STAT3 Pathway Inhibition.

Front Immunol. 2021

[8]
A phenotypic high-content, high-throughput screen identifies inhibitors of NLRP3 inflammasome activation.

Sci Rep. 2021-7-28

[9]
Baricitinib plus dexamethasone compared to dexamethasone for the treatment of severe COVID-19 pneumonia: A retrospective analysis.

J Microbiol Immunol Infect. 2021-10

[10]
Impact of high dose of baricitinib in severe COVID-19 pneumonia: a prospective cohort study in Bangladesh.

BMC Infect Dis. 2021-5-7

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索